Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

Bioheart, Inc., (OTC Bulletin Board: BHRT) announced today that Dr. Karl E. Groth, the Company's Chairman and CEO will speak at the 2010 Translational Regenerative Medicine Forum in Winston-Salem, North Carolina, on April 8.  Dr. Groth will discuss Bioheart's cell therapies for Congestive Heart Failure.  

Bioheart's therapies, which are currently in trials all over the world, aim to bring to patients, who otherwise would have little hope for a normal life, cutting edge therapies using as a basis, cells taken from their own fat or muscle tissue.  

The Conference is sponsored by the Regenerative Medicine Foundation, a not-for-profit organization created to advance new treatments and therapies based on tissue engineering and regenerative medicine. The Foundation believes that integrating life science and engineering disciplines will bring new clinical approaches to patients for the treatment of diseases affecting a wide range of tissues and organs.

By fostering collaboration between public and private initiatives, the Foundation capitalizes on the academic, industry and governmental resources in regenerative medicine and expedites the pace of research so that innovative therapies are developed and delivered to patients more rapidly. The Regenerative Medicine Foundation has been designed to be the connection point for a variety of interests, with education and interdisciplinary collaboration serving as the core and sustaining values of the organization.

The Conference focuses on best practices in clinical trials and GMP facilities, as well providing a forum to discuss regulatory and reimbursement challenges. In addition, the conference features a venture forum to introduce early-stage and later-stage companies to accredited and institutional investors.

Bioheart has recently announced plans for establishing five Centers of Excellence in Latin America to provide its cell therapy procedures to patients suffering from congestive heart failure (CHF) and peripheral arterial disease (PAD) beginning next month, April 2010.  In addition, Bioheart is conducting the first combined gene and cell therapy Phase I study approved by the FDA, the REGEN trial for MyoCell combined with SDF-1.  Bioheart has also begun a Phase II/III double-blinded study of its MyoCell product, the MARVEL trial, designed to obtain approval from the FDA for that product, and released in September of 2009 preliminary results of that study.  The study showed 35% improvement among treated patients in six-minute walk time, a result considered to be remarkable.

Dr. Karl Groth, Bioheart's Chairman and Chief Executive Officer said, "Making cell therapies available globally to patients suffering from cardiovascular disease is our goal.  We feel that our cell therapies have proven the capability to regenerate heart tissue and feel that our therapies constitute superior solutions for the resolution of heart failure issues.  We want to turn around the adverse impact on people's lives that CHF and PAD have created."